New labeling for Medtronic CRT
This article was originally published in The Gray Sheet
Executive Summary
Revised labeling cleared by FDA for Medtronic's cardiac resynchronization therapy devices without defibrillation will reflect the technology's reduced risk of mortality and hospitalization. The labeling expansion is based upon results from the 813-patient CARE-HF trial of the firm's InSync and InSync III CRT-P devices, presented in 2005 (1"The Gray Sheet" Sept. 12, 2005, p. 13). The data, showing a 36%-40% reduction in all-cause mortality, provides validation that CRT devices "should be routinely used in patients with moderate to severe heart failure," William Abraham, MD, Ohio State University, says...
You may also be interested in...
European Society of Cardiology Conference In Brief
Cypher DES: Johnson & Johnson/Cordis' Cypherdrug-eluting stent is significantly safer than bare-metal stents in complex cases where stents overlap, according to a meta-analysis of four Cypher trials presented by Martin Rothman, MD, London NHS Trust Hospital, at the European Society of Cardiology conference in Stockholm, Sept. 6. The analysis shows that overlapping Cypher stents are associated with a significantly lower rate of major adverse events than overlapping bare-metal stents - 7.4% versus 31.5% - and a lower rate of Q-wave myocardial infarction - 1.5% versus 4.6%. About 25% of all stent procedures require overlapping stents, according to Rothman. Studies included in the meta-analysis are SIRIUS, E-SIRIUS, DIRECT and SVELTE (1"The Gray Sheet" May 31, 2004, p. 13)...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.